Abstract：
UNASSIGNED: Analyze the impact of hyperbaric oxygen therapy on neuroprotection and recovery post severe traumatic brain injury (sTBI) resuscitation.
UNASSIGNED: Retrospective analysis of clinical data from 83 sTBI patients admitted between January 2022 to January 2024. Patients were divided into control (n = 41) and observation (n = 42) groups based on treatment received. Control received standard therapy, while the observation group received hyperbaric oxygen therapy. Effects on clinical outcomes, neuroinjury markers (S100β, GFAP, UCH-L1, NSE), neurotrophic factors (NGF, BDNF), neurological function indicators (NIHSS, CSS), and adverse reactions were compared.
UNASSIGNED: The observation group showed a higher total effective rate (80.95%) compared to control (60.98%) (p < 0.05). Neuroinjury markers decreased post-treatment in both groups, with the observation group lower (p < 0.05). NGF and BDNF levels increased post-treatment in both groups, with the observation group higher (p < 0.05). NIHSS and CSS scores decreased post-treatment in both groups, with the observation group lower (p < 0.05). No significant difference in adverse reactions between groups (p > 0.05).
UNASSIGNED: Hyperbaric oxygen therapy effectively treats sTBI by improving brain resuscitation success, reducing neuroinjury factors, enhancing neurotrophic factors, and promoting neurological function recovery, without increasing adverse reaction risk.
UNASSIGNED: Retrospective analysis of clinical data from 83 sTBI patients admitted between January 2022 to January 2024. Patients were divided into control (n = 41) and observation (n = 42) groups based on treatment received. Control received standard therapy, while the observation group received hyperbaric oxygen therapy. Effects on clinical outcomes, neuroinjury markers (S100β, GFAP, UCH-L1, NSE), neurotrophic factors (NGF, BDNF), neurological function indicators (NIHSS, CSS), and adverse reactions were compared.
UNASSIGNED: The observation group showed a higher total effective rate (80.95%) compared to control (60.98%) (p < 0.05). Neuroinjury markers decreased post-treatment in both groups, with the observation group lower (p < 0.05). NGF and BDNF levels increased post-treatment in both groups, with the observation group higher (p < 0.05). NIHSS and CSS scores decreased post-treatment in both groups, with the observation group lower (p < 0.05). No significant difference in adverse reactions between groups (p > 0.05).
UNASSIGNED: Hyperbaric oxygen therapy effectively treats sTBI by improving brain resuscitation success, reducing neuroinjury factors, enhancing neurotrophic factors, and promoting neurological function recovery, without increasing adverse reaction risk.
摘要：
目的:分析高压氧治疗对重型颅脑损伤(sTBI)复苏后神经保护及恢复的影响。方法:回顾性分析2022年1月至2024年1月收治的83例sTBI患者的临床资料。根据接受的治疗将患者分为对照组（n=41）和观察组（n=42）。对照组接受标准治疗,观察组给予高压氧治疗。对临床结果的影响，神经损伤标志物（S100β，GFAP,UCH-L1,NSE),神经营养因子(NGF，BDNF),神经功能指标(NIHSS，CSS),并对不良反应进行比较。结果:观察组总有效率(80.95%)高于对照组(60.98%)(P<0.05)。两组治疗后神经损伤标志物均下降，随观察组降低(P<0.05)。两组治疗后NGF和BDNF水平均升高，观察组高于对照组(P<0.05)。两组治疗后NIHSS和CSS评分均下降，随观察组降低(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论:高压氧治疗可提高脑复苏成功率,有效治疗sTBI,减少神经损伤因素，增强神经营养因子，促进神经功能恢复，不增加不良反应风险。
